MoA	Program	Targeted indications
RIPK1 inhibition	SIR9900	Neurodegenerative diseases
	SIR2446	Immune & Inflammatory diseases
Undisclosed	SIR2501	Neurodegenerative diseases
Undisclosed	SIR4156	Muscle degenerative diseases
Undisclosed	Small molecule	Undisclosed
Undisclosed	Therapeutic target / BDM	Neurodegenerative diseases
Early-stage programs